Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-10

AUTHORS

Rebecca A Dent, Geoffrey J Lindeman, Mark Clemons, Hans Wildiers, Arlene Chan, Nicole J McCarthy, Christian F Singer, Elizabeth S Lowe, Claire L Watkins, James Carmichael

ABSTRACT

INTRODUCTION: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADPribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). METHODS: Eligible patients who had received ≤1 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle. Dose modifications in a large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they experienced grade ≥2 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was continued prophylactically in subsequent cycles. All patients had measurable disease; tumor responses were evaluated according to RECIST (version 1.0). RESULTS: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane chemotherapy. The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and neutropenia (n = 11, 58%). Seven neutropenia events were reported in cohort 1 (four grade ≥3) and four in cohort 2 (two grade ≥3, including one event of febrile neutropenia). The median (range) dose intensity of paclitaxel was 57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2. Seven patients (37%) had a confirmed partial response; one patient remains on olaparib monotherapy without progression. CONCLUSIONS: The combination of olaparib and weekly paclitaxel was complicated by a significant clinical interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis. Given the encouraging response rate, alternative scheduling and dosing strategies should be considered (funded by AstraZeneca; ClinicalTrials.gov, NCT00707707). More... »

PAGES

r88

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/bcr3484

DOI

http://dx.doi.org/10.1186/bcr3484

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040423249

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24063698


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Paclitaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phthalazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Poly(ADP-ribose) Polymerase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triple Negative Breast Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Sunnybrook Health Science Centre", 
          "id": "https://www.grid.ac/institutes/grid.413104.3", 
          "name": [
            "National Cancer Center Singapore, Duke NUS, 169610, Singapore, Singapore", 
            "Sunnybrook Odette Cancer Center, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dent", 
        "givenName": "Rebecca A", 
        "id": "sg:person.01361171050.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361171050.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Melbourne Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416153.4", 
          "name": [
            "The Royal Melbourne Hospital & Walter and Eliza Hall Institute of Medical Research & University of Melbourne, Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lindeman", 
        "givenName": "Geoffrey J", 
        "id": "sg:person.01265205546.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265205546.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ottawa Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412687.e", 
          "name": [
            "The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clemons", 
        "givenName": "Mark", 
        "id": "sg:person.01216107435.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216107435.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitaire Ziekenhuizen Leuven", 
          "id": "https://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wildiers", 
        "givenName": "Hans", 
        "id": "sg:person.01171555551.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171555551.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Mount Hospital, Perth, WA, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chan", 
        "givenName": "Arlene", 
        "id": "sg:person.01106511331.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106511331.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Wesley Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417021.1", 
          "name": [
            "Wesley Medical Centre Brisbane, Auchenflower, QLD, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCarthy", 
        "givenName": "Nicole J", 
        "id": "sg:person.01162121553.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162121553.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of OB/GYN, Medical University of Vienna, General Hospital, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singer", 
        "givenName": "Christian F", 
        "id": "sg:person.0662165614.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662165614.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Wilmington, DE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lowe", 
        "givenName": "Elizabeth S", 
        "id": "sg:person.01217536755.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217536755.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Alderley Park, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watkins", 
        "givenName": "Claire L", 
        "id": "sg:person.01202410317.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202410317.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Alderley Park, Macclesfield, UK", 
            "Celgene, Seville, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carmichael", 
        "givenName": "James", 
        "id": "sg:person.01277127771.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277127771.78"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)60892-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000475882"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa071167", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002597130"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)60893-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010088435"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.3800528", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018899345", 
          "https://doi.org/10.1038/modpathol.3800528"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.3800528", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018899345", 
          "https://doi.org/10.1038/modpathol.3800528"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0707056", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019014675"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.9589", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020121676"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-009-0663-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023965648", 
          "https://doi.org/10.1007/s10549-009-0663-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-009-0663-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023965648", 
          "https://doi.org/10.1007/s10549-009-0663-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra1001389", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025958385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-11-1227", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032761921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa072113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033842397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0900212", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036199013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036499081", 
          "https://doi.org/10.1038/nature03443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036499081", 
          "https://doi.org/10.1038/nature03443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bcp.2012.03.018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036963078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70214-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037513376"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03445", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039649759", 
          "https://doi.org/10.1038/nature03445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03445", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039649759", 
          "https://doi.org/10.1038/nature03445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-1223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041711258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042257134", 
          "https://doi.org/10.1038/nrc1457"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042257134", 
          "https://doi.org/10.1038/nrc1457"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.295.21.2492", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043089674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-2425", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043371146"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043620626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.25.9820", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045520644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2011.03.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047581868"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-3045", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048367977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/07357900802709159", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050160837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.22.4216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074954336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077979904", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.1019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083942285"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.2520", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083947413"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-10", 
    "datePublishedReg": "2013-10-01", 
    "description": "INTRODUCTION: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADPribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).\nMETHODS: Eligible patients who had received \u22641 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle. Dose modifications in a large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they experienced grade \u22652 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was continued prophylactically in subsequent cycles. All patients had measurable disease; tumor responses were evaluated according to RECIST (version 1.0).\nRESULTS: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane chemotherapy. The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and neutropenia (n = 11, 58%). Seven neutropenia events were reported in cohort 1 (four grade \u22653) and four in cohort 2 (two grade \u22653, including one event of febrile neutropenia). The median (range) dose intensity of paclitaxel was 57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2. Seven patients (37%) had a confirmed partial response; one patient remains on olaparib monotherapy without progression.\nCONCLUSIONS: The combination of olaparib and weekly paclitaxel was complicated by a significant clinical interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis. Given the encouraging response rate, alternative scheduling and dosing strategies should be considered (funded by AstraZeneca; ClinicalTrials.gov, NCT00707707).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/bcr3484", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1022375", 
        "issn": [
          "1465-5411", 
          "1465-542X"
        ], 
        "name": "Breast Cancer Research", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer", 
    "pagination": "r88", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c08ef4df0a4b1ba2b7138a6325317fad74523bac9b3df4ccdc2a0820954b98cf"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24063698"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100927353"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/bcr3484"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040423249"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/bcr3484", 
      "https://app.dimensions.ai/details/publication/pub.1040423249"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2Fbcr3484"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/bcr3484'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/bcr3484'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/bcr3484'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/bcr3484'


 

This table displays all metadata directly associated to this object as RDF triples.

300 TRIPLES      21 PREDICATES      71 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/bcr3484 schema:about N014372a03bff478a8d754ec092512348
2 N09002f048ea643c9bb17e427c012ef93
3 N0abca2ceec49478c95c170d71c1bec9e
4 N388396f196374b15935d562741d871c8
5 N52842686649c4de78f8f569719b45c3f
6 N589d89875fcc4a199c711a03876d5c0a
7 N5e6ed22922b049d1ae3b1fcd578f241b
8 N60a1de3a4bfe41338ea0931cdb0ea789
9 N841d459e49684a29a0813afe2f42afd3
10 Nb2dc4b4974844da2a6a4d7998ea9314a
11 Nb6a2989867524fbdbb1fa07a1abb3d05
12 Nc20d3119c1b84a13917de78e0f84b83f
13 Ndde958d6e5464ce1a627f5add81979ac
14 Ne196517120e64fe0bc2fdc773d7def34
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N6d5385ed1d4240c2a6cfdcf00688dc19
18 schema:citation sg:pub.10.1007/s10549-009-0663-z
19 sg:pub.10.1038/modpathol.3800528
20 sg:pub.10.1038/nature03443
21 sg:pub.10.1038/nature03445
22 sg:pub.10.1038/nrc1457
23 https://app.dimensions.ai/details/publication/pub.1077979904
24 https://doi.org/10.1001/jama.295.21.2492
25 https://doi.org/10.1016/j.bcp.2012.03.018
26 https://doi.org/10.1016/j.cell.2011.03.020
27 https://doi.org/10.1016/s0140-6736(10)60892-6
28 https://doi.org/10.1016/s0140-6736(10)60893-8
29 https://doi.org/10.1016/s1470-2045(11)70214-5
30 https://doi.org/10.1056/nejmoa0707056
31 https://doi.org/10.1056/nejmoa071167
32 https://doi.org/10.1056/nejmoa072113
33 https://doi.org/10.1056/nejmoa0900212
34 https://doi.org/10.1056/nejmra1001389
35 https://doi.org/10.1080/07357900802709159
36 https://doi.org/10.1093/annonc/mds195
37 https://doi.org/10.1158/0008-5472.can-11-1227
38 https://doi.org/10.1158/1078-0432.ccr-06-3045
39 https://doi.org/10.1158/1078-0432.ccr-08-1223
40 https://doi.org/10.1158/1078-0432.ccr-11-2425
41 https://doi.org/10.1200/jco.2001.19.22.4216
42 https://doi.org/10.1200/jco.2009.25.9820
43 https://doi.org/10.1200/jco.2009.26.9589
44 https://doi.org/10.1200/jco.2010.28.15_suppl.1019
45 https://doi.org/10.1200/jco.2011.29.15_suppl.2520
46 schema:datePublished 2013-10
47 schema:datePublishedReg 2013-10-01
48 schema:description INTRODUCTION: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADPribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). METHODS: Eligible patients who had received ≤1 prior cytotoxic regimen for mTNBC were treated with olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle. Dose modifications in a large proportion of patients due to neutropenia resulted in enrollment of a second cohort of patients who, if they experienced grade ≥2 neutropenia in cycle 1, received granulocyte-colony stimulating factor, which was continued prophylactically in subsequent cycles. All patients had measurable disease; tumor responses were evaluated according to RECIST (version 1.0). RESULTS: Nineteen patients (cohort 1, n = 9; cohort 2, n = 10) received treatment; 15 had received prior taxane chemotherapy. The most frequent adverse events were diarrhea (n = 12, 63%), nausea (n = 11, 58%) and neutropenia (n = 11, 58%). Seven neutropenia events were reported in cohort 1 (four grade ≥3) and four in cohort 2 (two grade ≥3, including one event of febrile neutropenia). The median (range) dose intensity of paclitaxel was 57% (26 to 100%) in cohort 1 and 73% (29 to 100%) in cohort 2. Seven patients (37%) had a confirmed partial response; one patient remains on olaparib monotherapy without progression. CONCLUSIONS: The combination of olaparib and weekly paclitaxel was complicated by a significant clinical interaction, with higher-than-expected rates of neutropenia despite secondary prophylaxis. Given the encouraging response rate, alternative scheduling and dosing strategies should be considered (funded by AstraZeneca; ClinicalTrials.gov, NCT00707707).
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree true
52 schema:isPartOf N57916fe3512648e09e41a7911c3c3062
53 Nf08418ef7d37475a893c1f71e62bf8d2
54 sg:journal.1022375
55 schema:name Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
56 schema:pagination r88
57 schema:productId N21a70dbb9386442896016530fb3cc69b
58 N34d6987b5ac24862a99a7814b810c2b8
59 Nbb5a21ffe76f43319be278efea7bb012
60 Nccf444b15f4a4459ae56c03935f92629
61 Nd462fa5627434f1fa2822306ee9d6f21
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040423249
63 https://doi.org/10.1186/bcr3484
64 schema:sdDatePublished 2019-04-10T18:21
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N9d39d4c31bfa42cda5790b9deff73610
67 schema:url http://link.springer.com/10.1186%2Fbcr3484
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N014372a03bff478a8d754ec092512348 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Poly(ADP-ribose) Polymerase Inhibitors
73 rdf:type schema:DefinedTerm
74 N09002f048ea643c9bb17e427c012ef93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Humans
76 rdf:type schema:DefinedTerm
77 N0abca2ceec49478c95c170d71c1bec9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Adult
79 rdf:type schema:DefinedTerm
80 N0b9f1d0c5546498fb3e2f73ed5cdd8e3 rdf:first sg:person.01106511331.54
81 rdf:rest N0cc0fc5a8baa488b96d0c3cdd422667c
82 N0cc0fc5a8baa488b96d0c3cdd422667c rdf:first sg:person.01162121553.48
83 rdf:rest N7ed3226b8f264e278ac008f62b6538e5
84 N14d99953ad7b4631b57b3f8dc7f1d267 rdf:first sg:person.01265205546.72
85 rdf:rest N53c9871c027f423e8ad04323c60fd4fe
86 N21a70dbb9386442896016530fb3cc69b schema:name doi
87 schema:value 10.1186/bcr3484
88 rdf:type schema:PropertyValue
89 N34d6987b5ac24862a99a7814b810c2b8 schema:name pubmed_id
90 schema:value 24063698
91 rdf:type schema:PropertyValue
92 N388396f196374b15935d562741d871c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Aged
94 rdf:type schema:DefinedTerm
95 N3d29fc4d84f144efbc7f711b333f0530 rdf:first sg:person.01171555551.42
96 rdf:rest N0b9f1d0c5546498fb3e2f73ed5cdd8e3
97 N3d46a3d1c1474f1089487de70493fa74 rdf:first sg:person.01277127771.78
98 rdf:rest rdf:nil
99 N52842686649c4de78f8f569719b45c3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Triple Negative Breast Neoplasms
101 rdf:type schema:DefinedTerm
102 N53c9871c027f423e8ad04323c60fd4fe rdf:first sg:person.01216107435.90
103 rdf:rest N3d29fc4d84f144efbc7f711b333f0530
104 N57916fe3512648e09e41a7911c3c3062 schema:volumeNumber 15
105 rdf:type schema:PublicationVolume
106 N589d89875fcc4a199c711a03876d5c0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Treatment Outcome
108 rdf:type schema:DefinedTerm
109 N5e6ed22922b049d1ae3b1fcd578f241b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Piperazines
111 rdf:type schema:DefinedTerm
112 N60a1de3a4bfe41338ea0931cdb0ea789 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Middle Aged
114 rdf:type schema:DefinedTerm
115 N6d5385ed1d4240c2a6cfdcf00688dc19 rdf:first sg:person.01361171050.45
116 rdf:rest N14d99953ad7b4631b57b3f8dc7f1d267
117 N79d8893ca23249f4b4ced7d944c49128 schema:name Department of OB/GYN, Medical University of Vienna, General Hospital, Vienna, Austria
118 rdf:type schema:Organization
119 N7ed3226b8f264e278ac008f62b6538e5 rdf:first sg:person.0662165614.96
120 rdf:rest Nc3003ca2222143038c170df2375c9467
121 N83eea9ee293349548804f1aa36702382 rdf:first sg:person.01202410317.53
122 rdf:rest N3d46a3d1c1474f1089487de70493fa74
123 N841d459e49684a29a0813afe2f42afd3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Cohort Studies
125 rdf:type schema:DefinedTerm
126 N9d39d4c31bfa42cda5790b9deff73610 schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 Nb2dc4b4974844da2a6a4d7998ea9314a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Phthalazines
130 rdf:type schema:DefinedTerm
131 Nb6a2989867524fbdbb1fa07a1abb3d05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Paclitaxel
133 rdf:type schema:DefinedTerm
134 Nbb5a21ffe76f43319be278efea7bb012 schema:name nlm_unique_id
135 schema:value 100927353
136 rdf:type schema:PropertyValue
137 Nc20d3119c1b84a13917de78e0f84b83f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Antineoplastic Combined Chemotherapy Protocols
139 rdf:type schema:DefinedTerm
140 Nc3003ca2222143038c170df2375c9467 rdf:first sg:person.01217536755.50
141 rdf:rest N83eea9ee293349548804f1aa36702382
142 Nccf444b15f4a4459ae56c03935f92629 schema:name dimensions_id
143 schema:value pub.1040423249
144 rdf:type schema:PropertyValue
145 Nd462fa5627434f1fa2822306ee9d6f21 schema:name readcube_id
146 schema:value c08ef4df0a4b1ba2b7138a6325317fad74523bac9b3df4ccdc2a0820954b98cf
147 rdf:type schema:PropertyValue
148 Ndde958d6e5464ce1a627f5add81979ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Female
150 rdf:type schema:DefinedTerm
151 Nde40d5c72cd6473aaef1f466646a4d50 schema:name Mount Hospital, Perth, WA, Australia
152 rdf:type schema:Organization
153 Ne196517120e64fe0bc2fdc773d7def34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Neoplasm Metastasis
155 rdf:type schema:DefinedTerm
156 Nf08418ef7d37475a893c1f71e62bf8d2 schema:issueNumber 5
157 rdf:type schema:PublicationIssue
158 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
159 schema:name Medical and Health Sciences
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
162 schema:name Oncology and Carcinogenesis
163 rdf:type schema:DefinedTerm
164 sg:journal.1022375 schema:issn 1465-5411
165 1465-542X
166 schema:name Breast Cancer Research
167 rdf:type schema:Periodical
168 sg:person.01106511331.54 schema:affiliation Nde40d5c72cd6473aaef1f466646a4d50
169 schema:familyName Chan
170 schema:givenName Arlene
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106511331.54
172 rdf:type schema:Person
173 sg:person.01162121553.48 schema:affiliation https://www.grid.ac/institutes/grid.417021.1
174 schema:familyName McCarthy
175 schema:givenName Nicole J
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01162121553.48
177 rdf:type schema:Person
178 sg:person.01171555551.42 schema:affiliation https://www.grid.ac/institutes/grid.410569.f
179 schema:familyName Wildiers
180 schema:givenName Hans
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171555551.42
182 rdf:type schema:Person
183 sg:person.01202410317.53 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
184 schema:familyName Watkins
185 schema:givenName Claire L
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202410317.53
187 rdf:type schema:Person
188 sg:person.01216107435.90 schema:affiliation https://www.grid.ac/institutes/grid.412687.e
189 schema:familyName Clemons
190 schema:givenName Mark
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216107435.90
192 rdf:type schema:Person
193 sg:person.01217536755.50 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
194 schema:familyName Lowe
195 schema:givenName Elizabeth S
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217536755.50
197 rdf:type schema:Person
198 sg:person.01265205546.72 schema:affiliation https://www.grid.ac/institutes/grid.416153.4
199 schema:familyName Lindeman
200 schema:givenName Geoffrey J
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01265205546.72
202 rdf:type schema:Person
203 sg:person.01277127771.78 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
204 schema:familyName Carmichael
205 schema:givenName James
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277127771.78
207 rdf:type schema:Person
208 sg:person.01361171050.45 schema:affiliation https://www.grid.ac/institutes/grid.413104.3
209 schema:familyName Dent
210 schema:givenName Rebecca A
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361171050.45
212 rdf:type schema:Person
213 sg:person.0662165614.96 schema:affiliation N79d8893ca23249f4b4ced7d944c49128
214 schema:familyName Singer
215 schema:givenName Christian F
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662165614.96
217 rdf:type schema:Person
218 sg:pub.10.1007/s10549-009-0663-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023965648
219 https://doi.org/10.1007/s10549-009-0663-z
220 rdf:type schema:CreativeWork
221 sg:pub.10.1038/modpathol.3800528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018899345
222 https://doi.org/10.1038/modpathol.3800528
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/nature03443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036499081
225 https://doi.org/10.1038/nature03443
226 rdf:type schema:CreativeWork
227 sg:pub.10.1038/nature03445 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039649759
228 https://doi.org/10.1038/nature03445
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/nrc1457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042257134
231 https://doi.org/10.1038/nrc1457
232 rdf:type schema:CreativeWork
233 https://app.dimensions.ai/details/publication/pub.1077979904 schema:CreativeWork
234 https://doi.org/10.1001/jama.295.21.2492 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043089674
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1016/j.bcp.2012.03.018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036963078
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1016/j.cell.2011.03.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047581868
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1016/s0140-6736(10)60892-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000475882
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1016/s0140-6736(10)60893-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010088435
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1016/s1470-2045(11)70214-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037513376
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1056/nejmoa0707056 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019014675
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1056/nejmoa071167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002597130
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1056/nejmoa072113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033842397
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1056/nejmoa0900212 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036199013
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1056/nejmra1001389 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025958385
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1080/07357900802709159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050160837
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1093/annonc/mds195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043620626
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1158/0008-5472.can-11-1227 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032761921
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1158/1078-0432.ccr-06-3045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048367977
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1158/1078-0432.ccr-08-1223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041711258
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1158/1078-0432.ccr-11-2425 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043371146
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1200/jco.2001.19.22.4216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074954336
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1200/jco.2009.25.9820 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045520644
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1200/jco.2009.26.9589 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020121676
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1200/jco.2010.28.15_suppl.1019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083942285
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1200/jco.2011.29.15_suppl.2520 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083947413
277 rdf:type schema:CreativeWork
278 https://www.grid.ac/institutes/grid.410569.f schema:alternateName Universitaire Ziekenhuizen Leuven
279 schema:name Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
280 rdf:type schema:Organization
281 https://www.grid.ac/institutes/grid.412687.e schema:alternateName Ottawa Hospital
282 schema:name The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
283 rdf:type schema:Organization
284 https://www.grid.ac/institutes/grid.413104.3 schema:alternateName Sunnybrook Health Science Centre
285 schema:name National Cancer Center Singapore, Duke NUS, 169610, Singapore, Singapore
286 Sunnybrook Odette Cancer Center, Toronto, ON, Canada
287 rdf:type schema:Organization
288 https://www.grid.ac/institutes/grid.416153.4 schema:alternateName Royal Melbourne Hospital
289 schema:name The Royal Melbourne Hospital & Walter and Eliza Hall Institute of Medical Research & University of Melbourne, Melbourne, VIC, Australia
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.417021.1 schema:alternateName Wesley Hospital
292 schema:name Wesley Medical Centre Brisbane, Auchenflower, QLD, Australia
293 rdf:type schema:Organization
294 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
295 schema:name AstraZeneca, Alderley Park, Macclesfield, UK
296 Celgene, Seville, Spain
297 rdf:type schema:Organization
298 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
299 schema:name AstraZeneca, Wilmington, DE, USA
300 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...